Bridgebio Pharma Inc logo

Bridgebio Pharma Inc (BBIO)

$26.12

Bridgebio Pharma Inc (BBIO) Share Price Forecast
Currently 20 wall-street analysts regularly analyze the financials of Bridgebio Pharma Inc on a frequent basis to provide recommendations along with target share price. 20 analysts offering 12-month price forecasts for Bridgebio Pharma Inc (BBIO) have a share price target of $48. This median of share price forecast represents a 83.77% upside from the latest price of $26.12 as on 13.11.24.

Bridgebio Pharma Inc (BBIO) Price vs Consensus Price Target

Price
Target Price
As per the chart shown above, analysts believe that the Bridgebio Pharma Inc (BBIO) share price will touch around $48 in next 12-months.
Bridgebio Pharma Inc (BBIO) Share Price Forecast v/s Share Price Today
Below is a chart showing the percentage difference between Bridgebio Pharma Inc's share price and its median forecast price. As on 13.11.24, the difference is -46.92%

Bridgebio Pharma Inc (BBIO): Difference between Current Price & Median Forecasted Price

Difference in Percentage terms
Bridgebio Pharma Inc (BBIO) Share Price : Analyst Recommendation
Based on 20 analysts tracking and researching Bridgebio Pharma Inc (BBIO) share have buy recommendation on an average.

3M Ago1M AgoCurrent
Buy
11
12
12
Outperform
5
5
5
Hold
3
3
3
Underperform
0
0
0
Sell
0
0
0
Bridgebio Pharma Inc (BBIO) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

Moving Average
Price

200 Day Moving Average v/s Current Share Price

Moving Average
Price

FAQs

The latest share price target for Bridgebio Pharma Inc (BBIO) is $48, offered by 20 analysts offering 12-month price forecasts.

Bridgebio Pharma Inc (BBIO) has a maximum of 0.84 upside potential, based on 20 analysts offering 12-month price forecasts.

Based on 20 analysts tracking and researching Bridgebio Pharma Inc (BBIO), 85% have a buy recommendation. Remaining 15% have either sell or hold recommendations.

The latest share price of Bridgebio Pharma Inc (BBIO) is $26.12 as of 13/11/2024.

17 of total 20 analysts offering stock ratings for Bridgebio Pharma Inc BBIO have recommended buy rating.